查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1878270

发炎性肠道疾病治疗市场－2025-2030年预测

Inflammatory Bowel Syndrome Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计发炎性肠道疾病 (IBS) 治疗市场将从 2025 年的 257.78 亿美元成长到 2030 年的 333.41 亿美元，复合年增长率为 5.28%。

发炎性肠道疾病治疗市场分析

发炎性肠道疾病（IBS）是一种影响大肠的慢性消化系统疾病，主要表现为腹痛、腹胀、腹泻和便秘等症状。由于IBS是一种病因不明且目前尚无明确治疗方法方法的复杂疾病，治疗领域提供多种药物和治疗性介入，旨在控制和缓解症状。治疗方法主要分为药物治疗和非药理学的处置方法，每种方法都针对疾病管理的不同面向。

治疗类型

药物治疗是主要的治疗类别之一，包括泻药、止泻药、解痉药和抗忧郁症。这些药物针对特定的肠躁症症状，例如减少肠道收缩、增加排便频率和改善情绪，每种药物都采用针对特定机制的方法来减轻症状负担。

非药物疗法是治疗中同样重要的组成部分，包括饮食调整（例如增加膳食纤维摄取量和避免食用某些诱发食物）以及生活方式的改变（例如压力管理通讯协定和运动）。针灸和催眠疗法等辅助和替代疗法也为部分患者提供了额外的治疗选择，有助于缓解症状。

由于多种因素，包括新型创新治疗方法的研发、疾病盛行率的上升以及患者和医疗专业人员对该疾病认识的提高，肠躁症（IBS）治疗市场预计将会成长。然而，市场扩张也面临诸多挑战，例如某些药物价格上涨以及现有治疗方法对相当一部分患者群体疗效有限。

主要市场成长驱动因素

疾病盛行率和公众意识不断提高

发炎性肠道疾病（IBS）治疗市场的主要驱动力是病例数量的增加和人们对IBS认识的提高，诊断技术的引入和进步也进一步推动了这个市场的发展。 IBS盛行率的上升是成长要素，这归因于多种因素，包括饮食习惯的改变、生活方式的改变以及肠道菌丛组成的变化。除了生活方式因素外，肠道菌丛的变化也被认为与IBS的发生与发展密切相关。根据美国国家糖尿病、消化和肾臟疾病美国（NIDDK）统计，IBS影响着2500万至4500万美国人，这是一个需要治疗性介入的庞大患者群体。

患者和医疗保健专业人员对肠躁症 (IBS) 的认识不断提高，这也是推动市场发展的关键因素，因为对该疾病的更多了解可以促进早期诊断和治疗，从而有可能改善患者的治疗效果并增加就医意愿。

诊断技术的进步

诊断技术的进步提高了肠躁症（IBS）诊断的准确性和效率，从而推动了IBS治疗市场的成长。近年来，多种诊断测试的研发成功，不仅可以确诊IBS，还能排除其他具有类似症状的疾病。美国胃肠病学会推荐了特定的IBS诊断程序，例如大肠镜检查和粪钙卫蛋白检测，并制定了标准化的诊断通讯协定，从而能够准确识别疾病并选择合适的治疗方案。

市场挑战

肠躁症（IBS）治疗市场面临许多挑战，包括治疗费用高、现有治疗方法的认知度和疗效有限等。许多现有的IBS治疗方法仅部分有效，导致许多患者的症状无法充分缓解。某些药物，例如抗惊厥药和抗忧郁症，会产生严重的副作用，限制了其在IBS治疗中的临床应用。此外，包括生物製药在内的新型IBS疗法价格昂贵，难以负担，限制了部分患者族群获得治疗的机会。总而言之，这些因素严重阻碍了IBS治疗市场的发展以及患者获得最佳治疗方案的途径。

区域市场动态

北美洲

发炎性肠道疾病（IBS）治疗市场按地域划分为北美、南美、欧洲、中东和非洲以及亚太地区，其中亚太地区和北美占据主要市场份额。由于北美地区IBS发病率高，且许多大型製药公司在该地区设有分支机构，预计北美将在全球IBS市场中占据重要份额。根据加拿大肠道调查协会估计，5%至20%的加拿大人患有IBS，显示该地区IBS疾病负担沉重。

该地区拥有强大的医疗保健基础设施，公众和专业人士对肠躁症 (IBS) 的认识也很高，这使得开发针对该疾病的新型创新治疗方案成为在该地区运营的製药公司和研究机构的战略重点。

亚太地区

亚太地区肠躁症（IBS）治疗市场预计将迎来显着成长，这主要得益于该地区庞大且不断增长的人口以及日益上升的疾病盛行率。全部区域IBS的认知度不断提高，刺激了对诊断程序和治疗方案的需求。多家大型製药企业在该地区开展业务，促使其加大研发投入。大规模的潜在患者群体、不断提高的疾病认知度以及不断完善的医药基础设施，共同推动了亚太地区在预测期内成为全球IBS治疗市场成长的关键引擎。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
  • 市场驱动因素与未来趋势：探索市场驱动因素和关键趋势，以及它们将如何影响未来的市场发展。
  • 可操作的建议：利用这些见解，在动态环境中做出策略决策，并开拓新的商机和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

公司如何使用我们的报告范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2022年至2024年的历史数据和2025年至2030年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区分類的收入成长和预测评估，包括国家/地区
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

5. 发炎性肠道疾病治疗市场（按类型划分）

  • 介绍
  • 腹泻型大肠激躁症（IBS-D）
  • 便秘型大肠激躁症（IBS-C）
  • 大肠激躁症（IBS-PI）
  • 其他的

第六章 发炎性肠道疾病治疗市场：依治疗方法划分

  • 介绍
  • 药物治疗
  • 心理治疗
  • 营养补充品
  • 其他的

第七章 发炎性肠道疾病治疗市场：依地区划分

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第八章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第九章：公司简介

  • AbbVie Inc.
  • Ironwood Pharmaceuticals
  • Bayer AG
  • Probi AB
  • Salix Pharmaceuticals
  • Cosmo Pharmaceuticals
  • Pfizer
  • Takeda
  • Johnson & Johnson
  • UCB

第十章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061614661

The inflammatory bowel syndrome (IBS) treatment market, with a 5.28% CAGR, is projected to expand to USD 33.341 billion in 2030 from USD 25.778 billion in 2025.

Inflammatory Bowel Syndrome Treatment Market Analysis

Inflammatory bowel syndrome represents a chronic digestive disorder affecting the large intestine and manifesting through symptoms including abdominal pain, bloating, diarrhea, and constipation. As a complex condition without a definitive cure and unclear precise etiology, the IBS treatment industry encompasses diverse medications and therapeutic interventions designed to manage and alleviate symptomatic presentations. The treatment landscape is fundamentally divided into pharmacological and non-pharmacological approaches, each addressing different aspects of disease management.

Treatment Modalities

Pharmacological interventions constitute a primary treatment category, encompassing laxatives, anti-diarrheal medications, antispasmodics, and antidepressants. These pharmaceutical agents target specific IBS symptoms such as reduced bowel contractions, increased stool frequency, or mood enhancement, collectively seeking to alleviate the condition's symptomatic burden through mechanism-specific approaches.

Non-pharmacological therapies represent an equally important treatment dimension, incorporating dietary modifications such as increased fiber intake or elimination of specific trigger foods, alongside lifestyle improvements including stress management protocols and exercise regimens. Complementary and alternative therapies, including acupuncture and hypnosis, provide additional treatment options that certain patients find beneficial for symptom management.

The IBS treatment market is projected to experience growth driven by multiple factors including development of novel and innovative therapeutic solutions, rising disease prevalence, and increasing awareness among patients and healthcare professionals. However, market expansion faces significant challenges including high treatment costs for certain pharmaceuticals and limited efficacy of existing treatments for substantial patient populations.

Primary Market Drivers

Rising Disease Prevalence and Awareness

The inflammatory bowel syndrome treatment market is propelled fundamentally by escalating case numbers and heightened awareness of IBS, reinforced by introduction and advancement of diagnostic procedures. The increasing prevalence of inflammatory bowel syndrome represents a principal growth driver, attributed to various factors including dietary changes, lifestyle modifications, and alterations in gut microbiota composition. Changes in gut flora have been linked to IBS development alongside these lifestyle determinants. According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), IBS affects between 25 and 45 million Americans, underscoring the substantial patient population requiring therapeutic interventions.

Increasing awareness of IBS among both patients and healthcare professionals constitutes another critical market driver. Enhanced knowledge of the condition may facilitate earlier diagnosis and treatment initiation, potentially improving patient outcomes and expanding the treatment-seeking population.

Diagnostic Technology Improvements

Advancements in diagnostic technology are fueling IBS treatment market growth by enhancing the precision and efficiency of IBS diagnosis. Recent years have witnessed development of multiple diagnostic tests capable of confirming IBS diagnosis while excluding other conditions presenting with similar symptomatic profiles. The American College of Gastroenterology recommends specific diagnostic procedures for IBS diagnosis, including colonoscopies and fecal calprotectin assays, establishing standardized diagnostic protocols that facilitate accurate disease identification and appropriate treatment selection.

Market Challenges

The IBS treatment market confronts substantial challenges including high treatment costs and limited knowledge and efficiency of available therapeutic solutions. Many existing IBS treatments demonstrate only partial effectiveness, resulting in insufficient symptom relief for numerous patients. Certain medications such as antispasmodics and antidepressants may produce considerable adverse effects that restrict their clinical acceptability for IBS therapy. Additionally, newer IBS medications including biologics can be prohibitively expensive, limiting accessibility for certain patient populations. These factors collectively represent significant impediments to IBS treatment market development and patient access to optimal care.

Regional Market Dynamics

North America

The inflammatory bowel syndrome treatment market is geographically segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific, with Asia Pacific and North America accounting for major market shares. North America is anticipated to control significant portions of the global IBS market due to high disease incidence rates within the region and the presence of numerous major pharmaceutical companies. According to the Canadian Society of Intestinal Research, IBS is estimated to affect between 5% and 20% of Canadians, demonstrating substantial regional disease burden.

The region benefits from robust healthcare infrastructure and high levels of public and professional awareness regarding IBS. This favorable environment has established developing novel and innovative therapeutic solutions for the condition as a strategic priority for pharmaceutical companies and research institutions operating within the region.

Asia Pacific

The Asia Pacific IBS treatment market is predicted to experience significant growth driven by the region's large and expanding population combined with rising disease prevalence. IBS awareness is increasing throughout the area, stimulating demand for both diagnostic procedures and treatment alternatives. Multiple major pharmaceutical companies have established regional operations, resulting in increased investment in research and development activities. This combination of large addressable patient populations, growing disease awareness, and expanding pharmaceutical infrastructure positions Asia Pacific as a critical growth engine for global IBS treatment market expansion throughout the forecast period.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

  • INFLAMMATORY BOWEL SYNDROME TREATMENT MANAGEMENT MARKET BY TYPE
  • Irritable Bowel Syndrome with Diarrhea (IBS-D)
  • Irritable Bowel Syndrome with Constipation (IBS-C)
  • Post-infectious IBS (IBS-PI)
  • Others
  • INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY TREATMENT TYPE
  • Medications
  • Psychological Therapy
  • Dietary Supplements
  • Others
  • INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY GEOGRAPHY
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. INFLAMMATORY BOWEL SYNDROME TREATMENT MANAGEMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Irritable Bowel Syndrome with Diarrhea (IBS-D)
  • 5.3. Irritable Bowel Syndrome with Constipation (IBS-C)
  • 5.4. Post-infectious IBS (IBS-PI)
  • 5.5. Others

6. INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY TREATMENT TYPE

  • 6.1. Introduction
  • 6.2. Medications
  • 6.3. Psychological Therapy
  • 6.4. Dietary Supplements
  • 6.5. Others

7. INFLAMMATORY BOWEL SYNDROME TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. AbbVie Inc.
  • 9.2. Ironwood Pharmaceuticals
  • 9.3. Bayer AG
  • 9.4. Probi AB
  • 9.5. Salix Pharmaceuticals
  • 9.6. Cosmo Pharmaceuticals
  • 9.7. Pfizer
  • 9.8. Takeda
  • 9.9. Johnson & Johnson
  • 9.10. UCB

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations